Name: Thymosin Alpha 1 - 10mg
SKU: 168
Availability: InStock

Thymosin Alpha 1

Scientific Overview, Mechanism, Clinical Use and Evidence

Scientific Overview

Thymosin Alpha 1 (Tα1) is a 28-amino-acid immunomodulatory peptide derived from thymic tissue. It plays a role in adaptive immune regulation and immune resilience. Within immune-focused peptide frameworks, Tα1 is positioned as a regulator of immune balance rather than a stimulant.

Mechanism of Action

Tα1 modulates immune function by:

• Enhancing T-cell differentiation
• Supporting dendritic cell activation
• Regulating cytokine balance
• Influencing Toll-like receptor signaling pathways

Biological and Clinical Effects

Clinical research has explored Tα1 in viral infections, oncology adjunct therapy, and immune dysregulation states. Evidence suggests modulation of immune responsiveness rather than indiscriminate activation.

Time of Use / Treatment Duration

Viral infection support: 4–12 weeks. Oncology adjunct protocols: based on treatment cycle. Immune resilience protocols: 4–8 week structured courses. Reassessment of immune markers (CBC, inflammatory markers, clinical response) recommended.

Safety, Tolerability, and Precautions

Generally well tolerated. Use cautiously in autoimmune disorders.

Detailed References

Garaci E. (2007). Thymosin alpha 1: a historical overview. Annals of the New York Academy of Sciences, 1112:14–20.

Romani L, et al. (2011). Thymosin alpha 1 in immune modulation. Annals of the New York Academy of Sciences, 1217:13–20.

King R, et al. (2008). Thymosin alpha 1 in viral infection and cancer therapy. International Immunopharmacology, 8(8):1105–1112.

Sherman KE, et al. (2001). Thymosin alpha 1 therapy in chronic viral hepatitis. Hepatology, 33(6):1508–1514.

LaValle J. The Complete Guide to Peptides. Immune resilience framework and peptide-based immunomodulation.

Posology (Clinical Practice–Oriented)

In countries where approved:

• 1.6 mg subcutaneously, twice weekly

Investigational protocols in viral or immune conditions:

• 1.6 mg, 2–3 times weekly

Dosing may vary depending on indication.

Clinical Practice Framing

Thymosin Alpha 1 is best framed as an immune resilience peptide, integrated into broader strategies including nutrient status, sleep regulation, and stress reduction.

The peptides described in this material are intended strictly for research purposes only. They are not approved for human or veterinary use, clinical application, diagnosis, treatment, or prevention of any disease.

Any research involving these compounds must be conducted in compliance with applicable laws and regulations in the country where the research is performed, including prior approval by a duly constituted Ethics Committee or Institutional Review Board (IRB), where required.

RegenPept acts solely as a supplier of research-grade materials and assumes no responsibility or liability for the design, conduct, regulatory compliance, interpretation, or outcomes of any research involving these products.

Any dosage, administration protocols, or related information contained in this material are derived from publicly available scientific literature and are provided strictly for informational purposes. Such information does not constitute medical advice, therapeutic recommendation, or endorsement of any specific use by RegenPept.